Bristol-Myers Squibb is a global drugmaker selling cancer, blood-thinner, and immunology medicines like Revlimid, Eliquis, and Opdivo to hospitals, clinics, and pharmacies worldwide.
Money comes from patented prescription drugs, with gross margins around 70% and net margins near 19% on roughly USD 48B annual revenue. Sales are recurring as chronic-disease patients refill monthly, though patent expirations create lumpy cliffs.
Patent protection and complex biologics manufacturing keep generic rivals like Teva and Viatris at bay for now, but Revlimid's patent cliff and biosimilar competition from Amgen and Samsung Bioepis are eroding pricing power.
Buy (sector percentile 82) — value A-, growth A-, profitability A-, momentum C+, revisions B. Updated daily, sector-relative, identical for every user.
